<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203878</url>
  </required_header>
  <id_info>
    <org_study_id>09US05N375-Gold</org_study_id>
    <nct_id>NCT01203878</nct_id>
  </id_info>
  <brief_title>Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy</brief_title>
  <official_title>An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tennessee Clinical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Graceway Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tennessee Clinical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the effect of treating actinic keratoses of the face
      with imiquimod 3.75% cream followed by photodynamic therapy in comparison to treatment with
      imiquimod alone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Actinic keratoses are common skin lesions associated with solar ultraviolet radiation
      exposure. Some actinic keratoses may develop into skin cancers.

      Imiquimod 3.75% cream is an approved treatment for actinic keratoses that utilizes a regimen
      of application to the entire face or balding scalp of up to 2 packets of cream daily for two
      2-week cycles, separated by a 2-week no treatment interval.

      Photodynamic therapy with aminolevulinic acid (ALA) 20% topical solution is also an approved
      treatment for actinic keratoses. ALA is applied to actinic keratoses, and after an incubation
      period, is excited with light. Although approved as a lesion-directed treatment for actinic
      keratoses, treatment of a field (e.g. face) with photodynamic therapy is commonly performed.

      Treatment with photodynamic therapy followed by imiquimod 5% cream has been reported in
      patients with actinic keratoses, basal cell carcinoma and Bowen's disease, and treatment with
      imiquimod 5% cream followed by photodynamic therapy in patients with vulvar intraepithelial
      neoplasia. There are, however, no prior studies on the safety and/or efficacy of using
      topical imiquimod 3.75% in conjunction with photodynamic therapy in the treatment of actinic
      keratoses.

      This study will use an open-label parallel cohort design in which all patients will received
      treatment with imiquimod 3.75% cream, and subsequently will be randomized to either
      photodynamic therapy or observation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to reach target enrollment of 60 subjects
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actinic Keratosis Count</measure>
    <time_frame>Week 18 (4 weeks after randomization visit)</time_frame>
    <description>The percent change in actinic keratosis count as compared to the baseline lesion count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Clearance</measure>
    <time_frame>Week 18 (4 weeks after randomization visit)</time_frame>
    <description>The proportion of randomized patients with complete clearance of actinic keratoses in the treatment area (entire face).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic Appearance</measure>
    <time_frame>Week 18 (4 weeks after randomization visit)</time_frame>
    <description>Change (improvement) in investigator scores of cosmetic appearance of the treatment area (entire face) by objective and subjective assessments:
INVESTIGATOR COSMETIC ASSESSMENT 0 - Facial skin is smooth to the touch, without significant lines or unevenness in pigmentation
1 - Facial skin shows 1 area (cheeks, forehead, or the perioral area) of significant 3 - Facial skin shows 3 areas with significant roughness, dyspigmentation, or fine lines 2 - Facial skin shows 2 areas of significant roughness, dyspigmentation, or fine lines 4 - All are severe in severity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Imiquimod &amp; photodynamic therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imiquimod</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Photodynamic therapy</intervention_name>
    <description>Administered 4 weeks after completion of imiquimod therapy</description>
    <arm_group_label>Imiquimod &amp; photodynamic therapy</arm_group_label>
    <other_name>Levulan Kerasticks (aminolevulinic acid 20% solution)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation</description>
    <arm_group_label>Imiquimod &amp; photodynamic therapy</arm_group_label>
    <arm_group_label>Imiquimod</arm_group_label>
    <other_name>Zyclara (imiquimod 3.75% cream)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female adults; 18 and over

          -  At least 10 and no more than 30 clinically typical actinic keratoses on the face

        Exclusion Criteria:

          -  Hypertrophic actinic keratoses or other skin lesions on the head that might required
             excluded treatment during the study

          -  Known contraindication to treatment with imiquimod or photodynamic therapy

          -  Condition that would limit compliance, be a potential safety risk, or require therapy
             with an excluded treatment

          -  Systemically immunocompromised

          -  Pregnant or nursing

          -  Dermatologic disease and/or condition in treatment area that might exacerbated by
             treatment with imiquimod, cause difficulty with examination, or require therapy with
             an excluded treatment

          -  Participation in another clinical study

          -  Treatment within the past 60 days with:

               -  Ultraviolet therapy

               -  Systemic immunomodulators

               -  Chemotherapeutic or cytotoxic agents

               -  Investigational agents

          -  Treatment on the head within the past 60 days with:

               -  Imiquimod

               -  Photodynamic therapy

               -  Red or blue light source therapy

               -  Cryotherapy or chemotherapy

               -  Surgical excision or curettage

               -  Topical corticosteroids

               -  Laser

               -  Dermabrasion

               -  Chemical peel

               -  Topical retinoids

               -  Topical 5-fluorouracil

               -  Topical pimecrolimus or tacrolimus

               -  Topical diclofenac

          -  Treatment for actinic keratoses on the head within the past 60 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gold, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tennessee Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AboutSkin Dermatology and DermSurgery, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Girish Munavalli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology, Laser &amp; Vein Specialists of the Carolinas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AboutSkin Dermatology and DermSurgery, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Laser &amp; Vein Specialists of the Carolinas</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <results_first_submitted>November 13, 2014</results_first_submitted>
  <results_first_submitted_qc>November 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2014</results_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Imiquimod</keyword>
  <keyword>Photodynamic therapy</keyword>
  <keyword>Actinic keratoses</keyword>
  <keyword>Sequential therapy</keyword>
  <keyword>Therapeutic uses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited from practices of 3 dermatology clinics. First patient enrolled Nov 2010; last patient completed Dec 2011.</recruitment_details>
      <pre_assignment_details>Patients required to complete topical treatment phase prior to randomization to photodynamic therapy or observation. Three subjects discontinued prior to randomization, 2 for adverse events and 1 for withdrawal of consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Imiquimod Followed by Photodynamic Therapy</title>
          <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light</description>
        </group>
        <group group_id="P2">
          <title>Imiquimod Followed by Observation</title>
          <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation</description>
        </group>
        <group group_id="P3">
          <title>Non-randomized</title>
          <description>Imiquimod 3.75% applied to the entire face daily for up to 2 2-week cycles separated by a 2-week no treatment period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients completing week 18 visit</population>
      <group_list>
        <group group_id="B1">
          <title>Imiquimod Followed by Photodynamic Therapy</title>
          <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light</description>
        </group>
        <group group_id="B2">
          <title>Imiquimod Followed by Observation</title>
          <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation</description>
        </group>
        <group group_id="B3">
          <title>Non-Randomized</title>
          <description>Imiquimod 3.75% applied to the entire face daily for up to 2 2-week cycles separated by a 2-week no treatment period,</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="7"/>
                    <measurement group_id="B2" value="61" spread="6"/>
                    <measurement group_id="B3" value="66" spread="11"/>
                    <measurement group_id="B4" value="62" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total facial actinic keratosis count</title>
          <units>Patient facial actinic keratosis count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.3" spread="5.6"/>
                    <measurement group_id="B2" value="19.9" spread="5.6"/>
                    <measurement group_id="B3" value="18.0" spread="2.6"/>
                    <measurement group_id="B4" value="19.0" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Actinic Keratosis Count</title>
        <description>The percent change in actinic keratosis count as compared to the baseline lesion count</description>
        <time_frame>Week 18 (4 weeks after randomization visit)</time_frame>
        <population>Randomized patients with both a baseline and a week 18 actinic keratosis count. One patient in imiquimod/observation group did not have a baseline count and therefore was not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Imiquimod Followed by Photodynamic Therapy</title>
            <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light</description>
          </group>
          <group group_id="O2">
            <title>Imiquimod Followed by Observation</title>
            <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation</description>
          </group>
        </group_list>
        <measure>
          <title>Actinic Keratosis Count</title>
          <description>The percent change in actinic keratosis count as compared to the baseline lesion count</description>
          <population>Randomized patients with both a baseline and a week 18 actinic keratosis count. One patient in imiquimod/observation group did not have a baseline count and therefore was not included in the analysis.</population>
          <units>percent reduction in baseline count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" spread="19"/>
                    <measurement group_id="O2" value="83" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Clearance</title>
        <description>The proportion of randomized patients with complete clearance of actinic keratoses in the treatment area (entire face).</description>
        <time_frame>Week 18 (4 weeks after randomization visit)</time_frame>
        <population>Randomized patients with a week 18 actinic keratosis count.</population>
        <group_list>
          <group group_id="O1">
            <title>Imiquimod Followed by Photodynamic Therapy</title>
            <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light</description>
          </group>
          <group group_id="O2">
            <title>Imiquimod Followed by Observation</title>
            <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Clearance</title>
          <description>The proportion of randomized patients with complete clearance of actinic keratoses in the treatment area (entire face).</description>
          <population>Randomized patients with a week 18 actinic keratosis count.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmetic Appearance</title>
        <description>Change (improvement) in investigator scores of cosmetic appearance of the treatment area (entire face) by objective and subjective assessments:
INVESTIGATOR COSMETIC ASSESSMENT 0 - Facial skin is smooth to the touch, without significant lines or unevenness in pigmentation
1 - Facial skin shows 1 area (cheeks, forehead, or the perioral area) of significant 3 - Facial skin shows 3 areas with significant roughness, dyspigmentation, or fine lines 2 - Facial skin shows 2 areas of significant roughness, dyspigmentation, or fine lines 4 - All are severe in severity</description>
        <time_frame>Week 18 (4 weeks after randomization visit)</time_frame>
        <population>Randomized patients with both a baseline and a week 18 investigator cosmetic appearance score. One imiquimod/observation patient did not have an end of study investigator cosmetic appearance score.</population>
        <group_list>
          <group group_id="O1">
            <title>Imiquimod Followed by Photodynamic Therapy</title>
            <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light</description>
          </group>
          <group group_id="O2">
            <title>Imiquimod Followed by Observation</title>
            <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation</description>
          </group>
        </group_list>
        <measure>
          <title>Cosmetic Appearance</title>
          <description>Change (improvement) in investigator scores of cosmetic appearance of the treatment area (entire face) by objective and subjective assessments:
INVESTIGATOR COSMETIC ASSESSMENT 0 - Facial skin is smooth to the touch, without significant lines or unevenness in pigmentation
1 - Facial skin shows 1 area (cheeks, forehead, or the perioral area) of significant 3 - Facial skin shows 3 areas with significant roughness, dyspigmentation, or fine lines 2 - Facial skin shows 2 areas of significant roughness, dyspigmentation, or fine lines 4 - All are severe in severity</description>
          <population>Randomized patients with both a baseline and a week 18 investigator cosmetic appearance score. One imiquimod/observation patient did not have an end of study investigator cosmetic appearance score.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1"/>
                    <measurement group_id="O2" value="1.25" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks</time_frame>
      <desc>From study entry (Visit 1) to end of study (visit 5).</desc>
      <group_list>
        <group group_id="E1">
          <title>Imiquimod Followed by Photodynamic Therapy</title>
          <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light</description>
        </group>
        <group group_id="E2">
          <title>Imiquimod Followed by Observation</title>
          <description>Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation</description>
        </group>
        <group group_id="E3">
          <title>Non-Randomized</title>
          <description>Imiquimod 3.75% applied to the entire face daily for up to 2 2-week cycles separated by a 2-week no treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Verbatim</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore on lip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes labialis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fever blister</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Prickly feeling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Up to 30 days to review presentations and/or manuscripts. Up to an additional 60 days, if applicable, to file patent applications.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination (slow enrollment) leading to small numbers of subjects analyzed; missing measurement(s) on a patient</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Tennessee Clinical Research Center</organization>
      <phone>615-383-2400</phone>
      <email>jbiron@tnclinicalresearch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

